SOPHiA GENETICS SA (NASDAQ:SOPH) Sees Large Decrease in Short Interest

SOPHiA GENETICS SA (NASDAQ:SOPH) was the recipient of a significant decline in short interest during the month of December. As of December 31st, there was short interest totalling 31,400 shares, a decline of 15.1% from the December 15th total of 37,000 shares. Currently, 0.1% of the shares of the stock are sold short. Based on an average trading volume of 25,600 shares, the short-interest ratio is currently 1.2 days.

SOPHiA GENETICS Stock Performance

NASDAQ SOPH opened at $2.98 on Friday. The stock’s fifty day moving average is $3.29 and its two-hundred day moving average is $3.69. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.80 and a quick ratio of 3.59. SOPHiA GENETICS has a fifty-two week low of $2.70 and a fifty-two week high of $7.37.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.04). SOPHiA GENETICS had a negative net margin of 110.71% and a negative return on equity of 55.06%. The business had revenue of $15.85 million during the quarter, compared to analyst estimates of $15.90 million. During the same period last year, the company earned ($0.21) EPS. Equities analysts forecast that SOPHiA GENETICS will post -0.98 earnings per share for the current fiscal year.

Hedge Funds Weigh In On SOPHiA GENETICS

Several large investors have recently modified their holdings of the business. Green Alpha Advisors LLC acquired a new position in shares of SOPHiA GENETICS in the 3rd quarter valued at $79,000. Silverberg Bernstein Capital Management LLC purchased a new stake in shares of SOPHiA GENETICS in the 4th quarter valued at $70,000. Federated Hermes Inc. raised its holdings in shares of SOPHiA GENETICS by 57.5% in the 2nd quarter. Federated Hermes Inc. now owns 63,000 shares of the company’s stock valued at $289,000 after buying an additional 23,000 shares during the period. Finally, Principal Financial Group Inc. raised its holdings in shares of SOPHiA GENETICS by 6.3% in the 3rd quarter. Principal Financial Group Inc. now owns 1,455,142 shares of the company’s stock valued at $5,290,000 after buying an additional 86,764 shares during the period. Institutional investors and hedge funds own 31.59% of the company’s stock.

Analysts Set New Price Targets

Separately, Craig Hallum initiated coverage on SOPHiA GENETICS in a research note on Wednesday, December 18th. They issued a “buy” rating and a $11.00 price target on the stock. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $7.40.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.